Anife Gaffarova - Academia.edu (original) (raw)

Uploads

Papers by Anife Gaffarova

Research paper thumbnail of Dynamic of radiographic and ultrasonographic indices of hip joints in patients with ankylosing spondylitis under treatment with tumor necrotic factor ― alpha inhibitors

Medical alphabet, 2020

Background. Inflammation of the hip joints in ankylosing spondylitis (AS) is a frequent and sever... more Background. Inflammation of the hip joints in ankylosing spondylitis (AS) is a frequent and severe manifestation of the disease, which in 7–8 % of patients is accompanied by the requirements of hip joints prosthesis. In the treatment of hip arthritis associated with AS non-steroidal anti-inflammatory drugs (NSAIDs), sulfasalazine (SSZ) and tumor necrosis factor-alpha blockers were used. However, the influence of these treatment on the dynamics of structural changes in hip joints is not studied.Purpose. To evaluate the dynamics of clinical, radiologic and ultrasonographic indices of hip joints in patients with AS who take different treatment methods for 12 months: NSAIDs, SSZ and adalimumab (ADA).Materials and methods. Dynamic monitoring of 78 patients with AS (corresponding to the New York modified criteria of 1984), who also had clinical, ultrasonographic and radiographic signs of inflammation of hip joints. The patients were divided into three groups: patients of the group 1 (n = ...

Research paper thumbnail of Assessment of severity and pattern of irreversible organ damage in patients with systemic lupus erythematosus and systemic scleroderma

Medical alphabet, 2019

The article is devoted to the study of the degree and pattern of irreversible changes in the orga... more The article is devoted to the study of the degree and pattern of irreversible changes in the organs and systems of the body using the SLICC damage index in patients with systemic lupus erythematosus (SLE) and systemic scleroderma (SSc) with a disease duration of more than 5 years. Data were obtained from a high incidence of adverse changes in patients with SLE and SSc. In patients with SLE, adverse changes in the cardiovascular system, central nervous system in the form of acute cerebral circulation disorders and seizures, as well as venous thrombosis, damage to the organ of vision in the form of cataracts, proteinuria (more than 3.5 g per day) and alopecia prevailed. Patients with SSc more often developed lesions of the respiratory organs in the form of pulmonary fibrosis and pulmonary hypertension, the musculoskeletal system, skin and neuropathy of the cranial nerves and peripheral nerves.

Research paper thumbnail of FRI0407 TWO-YEAR Ultrasound Controlled Study of Hyaline Cartilage and Synovial Layer Structure of Hip Joints in Patients with Ankylosing Spondylitis During Treatment with Adalimumab

Spondyloarthritis – treatment, 2019

BL up to wk 52 according to clinical routine. Real-world effectiveness of secukinumab was assesse... more BL up to wk 52 according to clinical routine. Real-world effectiveness of secukinumab was assessed prospectively and analyzed as observed. Results: At BL, 641 PsA pts were included of whom 385 (60.1%) completed 52 wks so far (i.e. at the time of data cutoff for this interim analysis). 58.5% (n=375) of the pts were female and 41.5% (n=266) were male, mean age was 52.6 years. About 66% (n=424) were pre-treated with biologics. Mean PhGA improved from 5.3 at BL (n=571, 89.1%) to 2.5 at wk 52 (n=341, 53.2%). Mean absolute PASI improved from 8.1 at BL (n=211, 32.9%) to 1.2 at wk 52 (n=147, 22.9%). More than half of the documented pts (51 out of 94) achieved a 100% reduction (PASI 100) in skin symptoms at wk 52. The mean number of tender/swollen joints (ACR) was reduced from 7.6 (n=436, 68.0%)/3.9 (n=437, 68.2%) to 3.0 (n=241, 37.6%)/0.7 (n=242, 37.8%) at wk 52. The percentage of pts with CRP >5mg/L dropped from 43.0% at BL (n=230) to 36.6% at wk 52 (n=112). Mean PsAID-12 improved from 5.0 at BL (n=602, 93.9%) to 3.3 at wk 52 (n=343, 53.5%). The percentage of PsA pts with high disease activity (score ! 5) assessed by PsAID-12 dropped from 61.0% at BL (n=367) to 26.2% at wk 52 (n=90). MOS sleep scales did not change relevantly over time. With respect to pts with a BDI-II reduction of at least 3 score points, the mean value improved from 16.4 (mild depression) at BL to 8.0 (no depression) at wk 52 (n=123, 19.2%). Conclusion: Secukinumab reduced disease activity and improved QoL already within this subgroup of PsA pts. Thus, real-world data from the AQUILA study show that, in clinical routine, secukinumab treatment up to one year provides a clear benefit for PsA pts in clinical and QoL parameters.

Research paper thumbnail of Dynamic of radiographic and ultrasonographic indices of hip joints in patients with ankylosing spondylitis under treatment with tumor necrotic factor ― alpha inhibitors

Medical alphabet, 2020

Background. Inflammation of the hip joints in ankylosing spondylitis (AS) is a frequent and sever... more Background. Inflammation of the hip joints in ankylosing spondylitis (AS) is a frequent and severe manifestation of the disease, which in 7–8 % of patients is accompanied by the requirements of hip joints prosthesis. In the treatment of hip arthritis associated with AS non-steroidal anti-inflammatory drugs (NSAIDs), sulfasalazine (SSZ) and tumor necrosis factor-alpha blockers were used. However, the influence of these treatment on the dynamics of structural changes in hip joints is not studied.Purpose. To evaluate the dynamics of clinical, radiologic and ultrasonographic indices of hip joints in patients with AS who take different treatment methods for 12 months: NSAIDs, SSZ and adalimumab (ADA).Materials and methods. Dynamic monitoring of 78 patients with AS (corresponding to the New York modified criteria of 1984), who also had clinical, ultrasonographic and radiographic signs of inflammation of hip joints. The patients were divided into three groups: patients of the group 1 (n = ...

Research paper thumbnail of Assessment of severity and pattern of irreversible organ damage in patients with systemic lupus erythematosus and systemic scleroderma

Medical alphabet, 2019

The article is devoted to the study of the degree and pattern of irreversible changes in the orga... more The article is devoted to the study of the degree and pattern of irreversible changes in the organs and systems of the body using the SLICC damage index in patients with systemic lupus erythematosus (SLE) and systemic scleroderma (SSc) with a disease duration of more than 5 years. Data were obtained from a high incidence of adverse changes in patients with SLE and SSc. In patients with SLE, adverse changes in the cardiovascular system, central nervous system in the form of acute cerebral circulation disorders and seizures, as well as venous thrombosis, damage to the organ of vision in the form of cataracts, proteinuria (more than 3.5 g per day) and alopecia prevailed. Patients with SSc more often developed lesions of the respiratory organs in the form of pulmonary fibrosis and pulmonary hypertension, the musculoskeletal system, skin and neuropathy of the cranial nerves and peripheral nerves.

Research paper thumbnail of FRI0407 TWO-YEAR Ultrasound Controlled Study of Hyaline Cartilage and Synovial Layer Structure of Hip Joints in Patients with Ankylosing Spondylitis During Treatment with Adalimumab

Spondyloarthritis – treatment, 2019

BL up to wk 52 according to clinical routine. Real-world effectiveness of secukinumab was assesse... more BL up to wk 52 according to clinical routine. Real-world effectiveness of secukinumab was assessed prospectively and analyzed as observed. Results: At BL, 641 PsA pts were included of whom 385 (60.1%) completed 52 wks so far (i.e. at the time of data cutoff for this interim analysis). 58.5% (n=375) of the pts were female and 41.5% (n=266) were male, mean age was 52.6 years. About 66% (n=424) were pre-treated with biologics. Mean PhGA improved from 5.3 at BL (n=571, 89.1%) to 2.5 at wk 52 (n=341, 53.2%). Mean absolute PASI improved from 8.1 at BL (n=211, 32.9%) to 1.2 at wk 52 (n=147, 22.9%). More than half of the documented pts (51 out of 94) achieved a 100% reduction (PASI 100) in skin symptoms at wk 52. The mean number of tender/swollen joints (ACR) was reduced from 7.6 (n=436, 68.0%)/3.9 (n=437, 68.2%) to 3.0 (n=241, 37.6%)/0.7 (n=242, 37.8%) at wk 52. The percentage of pts with CRP >5mg/L dropped from 43.0% at BL (n=230) to 36.6% at wk 52 (n=112). Mean PsAID-12 improved from 5.0 at BL (n=602, 93.9%) to 3.3 at wk 52 (n=343, 53.5%). The percentage of PsA pts with high disease activity (score ! 5) assessed by PsAID-12 dropped from 61.0% at BL (n=367) to 26.2% at wk 52 (n=90). MOS sleep scales did not change relevantly over time. With respect to pts with a BDI-II reduction of at least 3 score points, the mean value improved from 16.4 (mild depression) at BL to 8.0 (no depression) at wk 52 (n=123, 19.2%). Conclusion: Secukinumab reduced disease activity and improved QoL already within this subgroup of PsA pts. Thus, real-world data from the AQUILA study show that, in clinical routine, secukinumab treatment up to one year provides a clear benefit for PsA pts in clinical and QoL parameters.